Roche haemophilia drug wins fast-track FDA designation
September 04, 2015 at 04:34 AM EDT
ZURICH, Sept 4 (Reuters) - Roche said on Friday it had won breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental haemophilia medicine, aiming for a piece of the $11 billion haemophilia drug market.
